BeStock  
Stocks › Biotechnology › NAMS

NewAmsterdam Pharma NAMS

US equityMarket cap rank #2621Biotechnology
$18.41 −$1.10 (-5.64%)
Market closed · Nov 20, 8:20 pm ET · Last extended-hours $18.32 -0.49%
Open$19.21
Prev close$19.51
Day range$18.29 – $19.78
Volume1.75M
Market cap$2.21B
P/E (TTM)–
Dividend yield–

Valuation

Multiples measured against the stock's own five-year history

Price / earnings-11.9x
CheapRich

Below its usual level · 27th percentile, 5-year average -9.4x

Price / book3.8x
CheapRich

Around its usual level · 60th percentile, 5-year average 3.1x

#4080 of 5330 stocks by PB (1 = cheapest)

Price / sales93.1x
CheapRich

Above its usual level · 63rd percentile, 5-year average 90.0x

#4939 of 5155 stocks by PS (1 = cheapest)

P/E over five years

-25x-16x-7x2xOct '21Apr '24Nov '26

Dashed line is the 5-year average; the shaded band is one standard deviation either side.

Morningstar fair value estimate

Fair value$25.71
Price vs. fair value-28.4%Trading below the estimate
Star rating★★★★☆
Economic moatNone
UncertaintyVery High
MultipleCurrentForward5y averagePercentile vs. own historyIndustry rank
PB 3.83 – 3.08 60% (pricier than usual) #4080 of 5330 (1 = cheapest)
PE -11.92 -9.27 -9.44 27% (cheaper than usual) –
PS 93.13 103.13 90.04 63% (pricier than usual) #4939 of 5155 (1 = cheapest)

Percentile is against this stock’s own 5-year valuation range: higher means it’s trading rich relative to its own history, lower means cheap relative to its own history — it is not a comparison against other companies. Forward multiples use consensus estimates for the next twelve months; a forward multiple below the current one usually signals analysts expect earnings to grow.

Discussion

No comments yet — be the first to weigh in on NAMS.

Sign in to join the discussion.

Scroll to Top